Revolutionary Gene Therapy Shows Promise in Treating Rare Genetic Disorder Affecting Liver and Lungs March 10, 2025
Beam Therapeutics’ Revolutionary Base Editing Therapy Shows Promise in Treating Alpha-1 Antitrypsin Deficiency March 10, 2025
Streamlining Success: Innovative Strategies for Efficient Cell and Gene Therapy Manufacturing March 10, 2025
Johnson & Johnson’s Aticaprant Setback: Implications for the Future of Kappa Opioid Receptor Drugs in Depression Therapy March 10, 2025
Johnson & Johnson Halts Aticaprant Development, Raising Questions Over Kappa Opioid Receptor Approach in Depression Treatment March 10, 2025
J&J’s Aticaprant Development Halt Signals Setback for Depression Drug Class and Biotech Sector March 9, 2025
Johnson & Johnson Halts Aticaprant Development, Shifting Focus as Market Dynamics Reshape Depression Drug Landscape March 9, 2025
Johnson & Johnson Halts Aticaprant Development, Sparking Doubts for Kappa Opioid Receptor Drugs in Depression Treatment March 9, 2025
Johnson & Johnson Halts Promising Depression Drug Aticaprant, Casting Shadow on Kappa Opioid Receptor Research March 9, 2025
Johnson & Johnson’s Aticaprant Setback Shakes Depression Treatment Landscape, Impacting Biotech Startups and Industry Optimism March 9, 2025
